Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE

Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL

30 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-Test Skip straight to the post-test if you have already participated in this activity.
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Overview

    Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment paradigm as well as practice guidelines. Understanding key differences between the covalent and non-covalent BTK inhibitors, along with recent clinical trial data, will allow the clinical care team to introduce and integrate newly approved practice-altering therapies into current treatment plans to best meet the needs of their diverse patients with CLL/SLL or MCL.

    In this educational activity, the expert faculty Chairperson will review the latest clinical evidence supporting the efficacy, safety, and tolerability of reversible, non-covalent BTK inhibitors to enhance incorporation into evidence-driven treatment sequencing for patients with CLL/SLL and MCL. The Chairperson will present a summary of the most relevant and timely advances with non-covalent BTK inhibitors while layering in their own personal, expert perspectives on how community care teams can contextualize this evidence to advance real-world clinical practice.

  • Disclosure of Conflicts of Interest

    Disclosure of Relevant Financial Relationships
    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty, Matthew S. Davids, MD, MMSc, reported the following relevant financial relationships or relationships he has with ineligible companies of any amount during the past 24 months: Consultant; AbbVie, Ascentage Pharma, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, BeiGene LTD, Bristol-Myers Squibb Company, Lilly, Genentech, Inc., Genmab, Janssen, Merck, MEI Pharma, Nuvalent, SecuraBio, Takeda Oncology & TG Therapeutics, Inc. Research grant; Novartis Pharmaceuticals Corporation, Ascentage Pharma & MEI Pharma.

    The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS: Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Melissa Duffy, PA-C; Adrienne N. Nedved, PharmD, MPA, BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships with any ineligible company of in any amount during the past 24 months. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck during the past 24 months.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Compare the novel MOA and the selectivity of reversible, non-covalent BTK inhibitors to that of irreversible, covalent BTK inhibitors
    • Apply real-world clinical evidence and clinical trial data on the efficacy and tolerability of reversible, non-covalent BTK inhibitors to incorporate them into evidence-driven treatment sequencing for patients with CLL/SLL or MCL
    • Integrate monitoring and management strategies for adverse events related to the use of reversible, non-covalent BTK inhibitors
  • Target Audience

    Community-based oncologists, hematologists, hematology oncologists, nurse practitioners, pharmacists (APPs), and other community-based practicing healthcare professionals with a role of treating and managing patients with CLL/SLL and MCL.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.
    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

     AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until July 23, 2025. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education JA4008106-0000-24-044-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 0.5 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

  • Provider(s)/Educational Partner(s)

    AXIS Medical Education enhances the knowledge, skills/strategy, and performance of the interprofessional healthcare team to ensure patients receive quality care, resulting in improved patient outcomes. We engage the interprofessional healthcare team in fair-balanced, scientifically rigorous, expert-led educational activities designed to foster lifelong learning that is applicable to clinical practice and patient-centered care. 

  • Commercial Support

    This activity is supported by an independent educational grant from Eli Lilly & Company, who has had no influence on, control of, nor input into the development or performance of the activity.

  • Disclaimer

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Disclosure of Unlabeled Use                                 
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Additional

    AXIS Contact Information  
    For information about the certification of this activity, please contact AXIS at info@axismeded.com  

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
Comments
  • Overview

    Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment paradigm as well as practice guidelines. Understanding key differences between the covalent and non-covalent BTK inhibitors, along with recent clinical trial data, will allow the clinical care team to introduce and integrate newly approved practice-altering therapies into current treatment plans to best meet the needs of their diverse patients with CLL/SLL or MCL.

    In this educational activity, the expert faculty Chairperson will review the latest clinical evidence supporting the efficacy, safety, and tolerability of reversible, non-covalent BTK inhibitors to enhance incorporation into evidence-driven treatment sequencing for patients with CLL/SLL and MCL. The Chairperson will present a summary of the most relevant and timely advances with non-covalent BTK inhibitors while layering in their own personal, expert perspectives on how community care teams can contextualize this evidence to advance real-world clinical practice.

  • Disclosure of Conflicts of Interest

    Disclosure of Relevant Financial Relationships
    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty, Matthew S. Davids, MD, MMSc, reported the following relevant financial relationships or relationships he has with ineligible companies of any amount during the past 24 months: Consultant; AbbVie, Ascentage Pharma, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, BeiGene LTD, Bristol-Myers Squibb Company, Lilly, Genentech, Inc., Genmab, Janssen, Merck, MEI Pharma, Nuvalent, SecuraBio, Takeda Oncology & TG Therapeutics, Inc. Research grant; Novartis Pharmaceuticals Corporation, Ascentage Pharma & MEI Pharma.

    The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS: Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Melissa Duffy, PA-C; Adrienne N. Nedved, PharmD, MPA, BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships with any ineligible company of in any amount during the past 24 months. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck during the past 24 months.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Compare the novel MOA and the selectivity of reversible, non-covalent BTK inhibitors to that of irreversible, covalent BTK inhibitors
    • Apply real-world clinical evidence and clinical trial data on the efficacy and tolerability of reversible, non-covalent BTK inhibitors to incorporate them into evidence-driven treatment sequencing for patients with CLL/SLL or MCL
    • Integrate monitoring and management strategies for adverse events related to the use of reversible, non-covalent BTK inhibitors
  • Target Audience

    Community-based oncologists, hematologists, hematology oncologists, nurse practitioners, pharmacists (APPs), and other community-based practicing healthcare professionals with a role of treating and managing patients with CLL/SLL and MCL.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.
    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

     AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until July 23, 2025. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education JA4008106-0000-24-044-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 0.5 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

  • Provider(s)/Educational Partner(s)

    AXIS Medical Education enhances the knowledge, skills/strategy, and performance of the interprofessional healthcare team to ensure patients receive quality care, resulting in improved patient outcomes. We engage the interprofessional healthcare team in fair-balanced, scientifically rigorous, expert-led educational activities designed to foster lifelong learning that is applicable to clinical practice and patient-centered care. 

  • Commercial Support

    This activity is supported by an independent educational grant from Eli Lilly & Company, who has had no influence on, control of, nor input into the development or performance of the activity.

  • Disclaimer

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Disclosure of Unlabeled Use                                 
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Additional

    AXIS Contact Information  
    For information about the certification of this activity, please contact AXIS at info@axismeded.com  

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule12 Dec 2024